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Mitochondrial DNA from two genetically unrelated
patients carrying the mutation at position 11778 that
causes Leber’s hereditary optic neuropathy has been
transferred with mitochondria into human mtDNA-less
r0206 cells. As analyzed in several transmitochondrial
cell lines thus obtained, the mutation, which is in the
gene encoding subunit ND4 of the respiratory chain
NADH dehydrogenase (ND), did not affect the synthesis,
size, or stability of ND4, nor its incorporation into the
enzyme complex. However, NADH dehydrogenase-
dependent respiration, as measured in digitonin-perme-
abilized cells, was specifically decreased by approxi-
mately 40% in cells carrying the mutation. This
decrease, whichwas significant at the 99.99% confidence
level, was correlated with a significantly reduced ability
of the mutant cells to grow in a medium containing
galactose instead of glucose, indicating a clear impair-
ment in their oxidative phosphorylation capacity. On
the contrary, no decrease in rotenone-sensitive NADH
dehydrogenase activity, using a water-soluble ubiqui-
none analogue as electron acceptor, was detected in
disrupted mitochondrial membranes. This is the first
cellular model exhibiting in a foreign nuclear back-
ground mitochondrial DNA-linked biochemical defects
underlying the optic neuropathy phenotype.
Leber’s hereditary optical neuropathy (LHON)1 has been
associated with several mitochondrial DNA (mtDNA) muta-
tions affecting in most cases mtDNA-encoded subunits of the
respiratory chain NADH dehydrogenase (NADH:coenzyme Q
oxidoreductase; E.C. 1.6.99.3; complex I). Four mutations, one
in the ND4 gene at position 11778 (1), one in the ND1 gene at
position 3460 (2, 3), one in the ND6 gene at position 14484 (4),
and one in the cytochrome b gene at position 15257 (5, 6), are
considered primary mutations, in that they can cause the dis-
ease in the absence of other mutations. There are, in addition,
mild LHON mutations at less highly conserved positions in the
ND genes, and also in the cytochrome c oxidase subunit genes,
which appear to act synergistically with each other or with
primary mutations in producing the disease phenotype (7).
Mutations at position 4160 of the ND1 gene (8) or at position
14459 of the ND6 gene (9) have been found to be associated
with syndromes including, besides the typical LHON defects,
alterations of the central nervous system.
The 11778 mutation accounts for at least 50% of the Euro-
pean, North American, and Australian LHON cases (1, 10, 11),
but the identification of a clear biochemical effect associated
with the mutation has been elusive. The G to A transition
causes a conserved arginine to be replaced by a histidine in
ND4. Larsson et al. (12) reported a reduction of about 50% in
the malate/glutamate- or pyruvate/malate-dependent respira-
tion rate in intact mitochondria from muscle biopsy material
from patients with the 11778 mutation, while succinate-de-
pendent respiration appeared to be normal. However, they
failed to detect a reduction in NADH-cytochrome c oxidoreduc-
tase enzyme activity in disrupted mitochondria. This result
was surprising because malate/glutamate- or pyruvate/malate-
driven respiration depends on respiratory chain NADH dehy-
drogenase activity. Other investigators, using immortalized
lymphoblasts from patients carrying the 11778 mutation (13),
have also reported a decrease in the rate of rotenone-sensitive
oxidation of NAD-linked substrates by intact mitochondria, but
no decrease in rotenone-sensitive NADH:2,6-dichlorophenolin-
dophenol oxidoreductase activity in disrupted mitochondrial
membranes. The absence of a decrease in NADH:2,3-dime-
thoxy-5-methyl-6-n-undecyl-p-benzoquinone (UBQ) oxidore-
ductase activity was also reported for mitochondrial mem-
branes from platelets (14).
Another intriguing aspect of LHON is the low penetrance of
the disease, which has pointed to the possible role of a nuclear
factor(s) in the manifestation of the disease phenotype. Only
about 30% of males and 10% of females carrying the 11778
mutation actually suffer visual loss (11). The predominance of
males has led to the hypothesis of an X-chromosome-linked
factor being involved in the disease (11, 15, 16). It should be
noted that at least two genes for complex I have been assigned
to the X-chromosome in rodents (17).
We have transferred mitochondria from patients carrying
the 11778 mutation in their mtDNA into the mtDNA-less cell
line r0206 (18) to determine whether the biochemical defects
found in patients’ cells would be manifested also in the absence
of the patients’ nuclear background. The r0206 nuclear back-
ground supports normal rates of respiration in transmitochon-
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drial cell lines constructed with cytoplasts from normal cells
(19). By contrast, in this “normal” nuclear background, the
11778 mutation caused a statistically significant reduction in
the rate of glutamate/malate-driven respiration, but not in the
rate of succinate/glycerol-3-phosphate (glycerol-3-P)-driven
respiration. We have also shown that, under conditions in
which cells are forced to rely almost exclusively on oxidative
phosphorylation to produce ATP, i.e. in medium containing
galactose instead of glucose, the mutation significantly reduced
the growth rate.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture Conditions—Skin fibroblast cultures Le1 (cell
line TC89-1973 of the Genetics Core, Mental Retardation Research
Center, The Kennedy Institute, Baltimore, MD) and Le2 were estab-
lished from LHON patients 1 and 2 by standard procedures. Patient 1,
a male, has had longstanding (possibly lifelong) poor vision. When first
examined clinically at age 35, he exhibited a mild impairment of visual
acuity, with paracentral scotomas and reduced color vision. Three years
later, his visual acuity and color vision had significantly improved,
although there was persistence of paracentral scotomas and diffuse
optic atrophy, as revealed by ophthalmoscopy. He is a member of a large
pedigree with matrilineal transmission of LHON, in which some mem-
bers have experienced the typical acute loss of vision normally seen in
this disease, and others, like patient 1, have had long standing poor
vision. Patient 2, also a male, suffered acute loss of vision at age 21, had
no known family history of LHON, and his vision did not recover.
Patients 1 and 2 were 49 and 33 years old, respectively, when skin
biopsies and blood samples were taken. The GM03651C and GM03652A
fibroblast strains, derived from presumably normal individuals, were
obtained from the NIGMS Human Genetic Mutant Cell Repository,
Coriell Institute for Medical Research (Camden, NJ).
All fibroblast strains were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
The osteosarcoma-derived cell line 143B.TK2 (ATCC CRL 8303), here-
after referred to as 143B, and r0206, the r0 cell line used in this study,
were cultured as described previously (18). pT3 (19) is a transmitochon-
drial cell line constructed with enucleated myoblasts from a myoclonic
epilepsy and ragged red fiber syndrome patient, but lacking the mito-
chondrial tRNALys gene mutation causing the disease. pT3 was main-
tained in DMEM supplemented with 5 or 10% FBS and 100 mg of
5-bromodeoxyuridine/ml.
Mitochondria Transfer into ro206 Cells—Mitochondria-mediated
transformation of r0206 cells with fibroblasts was carried out as de-
scribed previously (18), by fusing fibroblasts enucleated with cytocha-
lasin B with r0206 cells in the presence of 40% polyethylene glycol 1500
(BDH). Mitochondrial transformants were selected in DMEM contain-
ing 100 mg of 5-bromodeoxyuridine/ml and supplemented with 10%
dialyzed FBS, or, in the case of C1.C11, in DMEM supplemented with
5% dialyzed FBS. This clone was subsequently shown to be resistant to
5-bromodeoxyuridine.
Growth Measurements—These were made by plating samples of 105
cells on 10-cm Petri dishes in 10 ml of the appropriate medium (DMEM,
which contains 4.5 mg of glucose/ml and 0.11 mg of pyruvate/ml, or
DMEM lacking glucose and containing 0.9 mg of galactose/ml and 0.5
mg of pyruvate/ml (20), both supplemented with 10% dialyzed FBS),
incubating them at 37 °C for 7 days and performing cell counts at daily
intervals.
[35S]Methionine Labeling and Immunoprecipitation of Mitochondrial
Translation Products—Cells were labeled for 1 h with [35S]methionine
(1000 Ci/mmol; 220 mCi/ml) in the presence of 100 mg of emetine/ml, as
described previously (19). For immunoprecipitation experiments, cells
were labeled and chased as follows. 106 cells were exposed to 40 mg of
chloramphenicol/ml for 22 h, then washed and labeled for 2 h with 1.7
mCi of [35S]methionine in 8 ml of DMEM lacking methionine and
containing 100 mg of cycloheximide/ml. Following the pulse, the cells
were washed, and grown further for 18 h in the presence of unlabeled
methionine and in the absence of any inhibitor. The cells were then
harvested by trypsinization and pooled with ;4 3 107 carrier cells for
the isolation of mitochondria. Reference is made to previous work for
the methods used to immunoprecipitate complex I with antibodies
directed against the 49-kDa subunit (21) or the cytochrome c oxidase
complex with antibodies directed against the COOH-terminal unde-
capeptide of subunit II (CO II; 22) from a Triton X-100 lysate of
mitochondria.
DNA Analysis—Total DNA was extracted from peripheral blood cells
of the patients and from fibroblast cultures derived from skin biopsies
and subjected to polymerase chain reaction (PCR) amplification of a
portion of the ND4 gene, using primers between nucleotide positions
11429 and 11448 and between positions 11910 and 11929. The DNA
amplified from blood cells was sequenced by the dideoxy chain termi-
nation method (23) and found to exhibit the G to A transition at position
11778. The PCR products were checked for heteroplasmy by digestion
with SfaNI and MaeIII (24). The G to A mutation abolishes the SfaNI
site normally present and creates aMaeIII site. DNA was also extracted
from Le1- and Le2-derived transmitochondrial cell lines, and the region
between nucleotide positions 11575 and 11915 was amplified by PCR
using 20-nucleotide long primers. The PCR products were incubated
with SfaNI. pBluescript II KS1 plasmid DNA, which contains four
SfaNI sites, was added to a portion of the digestion mixture to verify
that all SfaNI sites had been cut completely. The reaction mixtures
were then analyzed by electrophoresis in a 1.5% agarose gel.
Quantification of mtDNA in total DNA samples from the r0 cell
transformants and from 143B cells (isolated with an Applied Biosys-
tems 340 DNA extractor) was carried out by slot blot hybridization,
using as a probe plasmid pTZ18/K4, containing the human mtDNA
fragment between positions 41 and 2578, labeled with 32P by random
priming (25). To correct for possible quantitative variations among
samples, the same membrane was incubated with a 32P-labeled nuclear
DNA probe, i.e. a plasmid containing a 498-base pair portion of 28 S
rDNA (26). Quantification of the hybridization signals was performed
by analyzing the blots with a PhosphorImager (Molecular Dynamics).
Oxygen Consumption in Intact and Digitonin-permeabilized Cells—
Total oxygen consumption rates in intact cells were measured as de-
scribed (18), except that the medium in the chamber contained 5%
dialyzed calf serum, instead of 5% dialyzed FBS. Oxygen consumption
measurements in digitonin-permeabilized cells were done as previously
detailed (27).
Enzyme Assays—For these assays, the mitochondrial fraction was
isolated from ;2 ml of packed cells as described previously (28), resus-
pended at 3 mg of protein/ml in cold 10 mM Tris-HCl, pH 6.7 (25 °C),
0.25 M sucrose, and sonicated in an ice-water bath for 60 s in six 10-s
pulses separated by intervals of at least 30 s. The rate of transfer of
electrons from NADH to 2,3-dimethoxy-5-methyl-6-n-decyl-1,4-benzo-
quinone (decylubiquinone; DB) was assayed as previously detailed (29).
In particular, this activity was measured, at a protein concentration of
approximately 10 mg/ml, in buffer containing 50 mM Tris-HCl, pH 7.5,
50 mM NaCl, and 1 mM KCN. The reaction mixture, containing 20 mM
NADH, was preincubated at 30 °C for 4 min, and the reaction was then
started by the addition of DB (e 5 14.0 mM21zcm21 at 278 nm) to 2 mM.
The oxidation of NADH was monitored at 340 mM minus 400 nm (e 5
6.3 mM21zcm21). The NADH:DB oxidoreductase activity was .95% sen-
sitive to 400 nM rotenone.
Cytochrome c oxidase activity was assayed, using the total sonicated
mitochondrial fraction, as described previously (30), with 31 mM horse
heart cytochrome c in a 1-ml reaction volume containing 6–10 mg of
protein. Digitonin (Serva) was added to the sonicated mitochondrial
fraction to 0.6% at least 15 min before the assay (31). Only the KCN-
sensitive activity was measured.
Protein concentration was determined by the Lowry method (32) in
the samples used for the NADH:DB oxidoreductase assay, and by the
method of Bradford (33) in the samples used for the cytochrome c
oxidase assay.
RESULTS
Presence of 11778 ND4 Mutation in Cells from LHON Pa-
tients and in r0 Transformants Constructed with LHON Pa-
tient-derived Fibroblasts—The mtDNA mutation at position
11778 was detected in PCR-amplified DNA from peripheral
blood cells from patients 1 and 2 by DNA sequencing. The
mutation was present in homoplasmic form in both patients, as
verified by the disappearance of a SfaNI site and the specific
appearance of a MaeIII site in the patient’s blood cells and in
fibroblast cultures, Le1 and Le2, derived from patients 1 and 2,
respectively. The DNA from the fibroblasts and blood of pa-
tients 1 and 2 did not exhibit any other known LHON-associ-
ated primary or secondary mutations, in particular those at
positions 3394, 3460, 4160, 4216, 4917, 5244, 7444, 9438, 9804,
13708, 14484, 15257, and 15812.
The mitochondria from the Le1 and Le2 fibroblast strains
were transferred to the human mtDNA-less line r0206 by cy-
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toplast 3 r0 cell fusion (18). Of several mitochondrial transfor-
mant clones isolated, four, i.e. Le1.3.1, Le1.4.2, Le2.F10, and
Le2.H4, were subjected to molecular and biochemical analysis.
These were all homoplasmic for the 11778 mutation (data not
shown). Control cell lines included mitochondrial transformant
C1.C11, derived from fibroblast strain GM03651C; transfor-
mants C2.C1, C2.H1, and C2.A8, derived from fibroblast strain
GM03652A; normal transformant pT3, derived from a myo-
blast strain established from a myoclonic epilepsy and ragged
red fiber syndrome patient, and the 143B cell line. None of the
controls carried the 11778 mutation, as detected by PCR and
SfaNI digestion. Quantification of mtDNA in the transmito-
chondrial cell lines showed that their mtDNA copy number
varied between 40 and 150% of that of 143B cells (9100 mtDNA
molecules per cell (18)), without any significant difference be-
tween the transformants derived from the two patients carry-
ing the 11778 mutation and the control transformants.
Lack of Effect of the 11778 Mutation on the Rate of Synthesis
of ND4 Subunit and Assembly of Complex I—Experiments
were carried out to test whether the 11778 mutation in the
ND4 gene affects the synthesis or stability of the ND4 subunit
or the assembly of complex I. Fig. 1a shows the electrophoretic
patterns, after a 1-h pulse labeling with [35S]methionine in the
presence of the cytosolic protein synthesis inhibitor emetine, of
the mitochondrial translation products of the fibroblast cul-
ture, Le1, derived from patient 1 and of a control fibroblast
culture, GM03651C. The ND4 polypeptide exhibits the same
electrophoretic mobility and is labeled to the same relative
extent in the two cultures, as determined by densitometric
analysis of appropriate exposures of the autoradiogram.
Previous work (27) had pointed to a role of the ND4 subunit
in the assembly of complex I. In the present investigation, to
determine whether the 11778 mutation affects the assembly of
complex I, antibodies against the 49-kDa subunit of complex I,
a nuclear-encoded subunit, which are able to immunoprecipi-
tate the entire complex I from a Triton X-100 lysate of mito-
chondria (21), were used. For this experiment, mitochondrial
transformant cells Le1.4.2 were labeled for 2 h with [35S]me-
thionine in the presence of cycloheximide, a reversible inhibitor
of cytosolic protein synthesis, and then chased for 18 h in
medium lacking inhibitors. Fig. 1b shows that the ND4 sub-
unit, as well as the other mtDNA-encoded subunits of the
respiratory chain NADH dehydrogenase, are incorporated into
this complex in cells carrying the 11778 mutation to the same
extent as in the wild-type C1.C11 transformant cells.
Respiration Capacity of r0 Cell Transformants Carrying the
11778 ND4 Mutation—Fig. 2 shows the total O2 consumption
rate in the intact r0 transformant cells containing the 11778
mutation, in the control transformants, and in 143B cells.
There is appreciable variation in O2 consumption rate both
among the control transformants and among the mutant trans-
formants. In particular, two of the three control transformants
derived from fibroblast strain GM03652A, i.e. C2.C1 and
C2.H1, exhibited a significantly lower respiration rate than the
third transformant, C2.A8, derived from the same cell line. The
variability in respiration activity among transformants carry-
FIG. 1. Electrophoretic patterns of [35S]methionine pulse-labeled mitochondrial translation products from control and LHON
fibroblasts (a), and immunoprecipitates obtained by incubating samples of Triton X-100 lysates from a control and a LHON r0
transformant with antibodies against the bovine 49-kDa subunit of complex I or the human CO II subunit (b). Proteins in both panels
were run on an exponential gradient polyacrylamide-SDS gel (34) and exposed for fluorography (35). a, cells were labeled with [35S]methionine for
1 h in the presence of emetine and immediately harvested. C1, fibroblast strain GM03651C; Le1, fibroblast strain derived from patient 1; ND1,
ND2, ND3, ND4, ND4L, ND5, and ND6, subunits of the respiratory chain NADH dehydrogenase; CO I, CO II, and CO III, subunits of cytochrome
c oxidase; A6 and A8, subunits of the H1-ATPase; Cyt b, cytochrome b. b, the first two lanes show the patterns of labeled proteins in r0
transformants C1.C11 and Le1.4.2 after exposure to [35S]methionine for 2 h in the presence of cycloheximide, followed by a chase for 18 h in
medium containing unlabeled methionine and no inhibitors. Proteins are identified as in panel a. The following six lanes show the results of
immunoprecipitation experiments carried out with 0.5% Triton X-100 lysates from the C1.C11 or Le1.4.2 transformant and normal serum
antibodies (NS), or antibodies against the purified 49-kDa subunit of bovine complex I (49; Ref. 36), or antibodies against the COOH-terminal
undecapeptide of cytochrome c oxidase subunit II (CO II; Ref. 22). Arrows at left indicate ND subunits immunoprecipitated by the 49-kDa specific
antibodies. The indicated polypeptides are not present in the NS control or in the CO II control. Arrows at right indicate subunits precipitated by
the CO II-specific antibodies.
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ing the same mtDNA, a phenomenon which had been previ-
ously observed (37), was not correlated with any difference in
either growth rate (see below) or mtDNA content of the trans-
formants. Despite the variability just mentioned, it is clear that
the average respiratory activity of the cell lines carrying the
11778 mutation is decreased relative to that of the control cell
lines; however, the difference is not statistically significant (p
5 0.15).
Because the 11778 mutation occurs in a gene coding for a
subunit of the respiratory chain NADH dehydrogenase, it was
expected that the primary defect accounting for the decrease in
respiration would be in the respiratory NADH dehydrogenase.
To obtain evidence on this point, the activity of the individual
components of the mitochondrial respiratory chain was meas-
ured by a polarographic analysis of digitonin-permeabilized
cells. Cells were treated with the detergent, thereby washing
out the endogenous substrates (38), and then, the rates at
which the cells consumed oxygen in response to different sub-
strates were measured (27, 38, 39). With malate and glutamate
as substrates, the corresponding dehydrogenases generate
FIG. 3. Polarography assays on dig-
itonin-permeabilized r0 cell transfor-
mants, carried out using different
substrates. a, the hatched bars repre-
sent glutamate/malate-driven respira-
tion, the shaded bars, succinate/glycerol-
3-P-driven respiration, and the white
bars, TMPD/ascorbate-driven respiration,
determined on 0.5–1 3 107 cells. b, for
each cell line, glutamate/malate-driven
respiration was normalized to succinate/
glycerol-3-P-driven respiration. The
dashed horizontal lines represent the
means for the controls and the LHON
transformants. p, probability, according
to the Student’s t-test, that the two
groups of samples belong to two popula-
tions having the same mean was calcu-
lated using Microsoft Excel software. The
data for 143B were taken from Hofhaus
and Attardi (27). Error bars represent two
S.E. of the mean.
FIG. 2. Total respiration rate of r0
cell transformants. Respiration rates
were measured on approximately 5 3 106
cells. Error bars represent two standard
errors of the mean. The data for 143B and
pT3 were taken from Chomyn et al. (19).
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NADH in the mitochondrial matrix, which is oxidized by the
NADH:ubiquinone oxidoreductase (complex I). The electrons
from NADH are transferred via the ubiquinol:cytochrome c
oxidoreductase (complex III) and the cytochrome c:O2 oxi-
doreductase (complex IV) to oxygen. Using succinate and glyc-
erol 3-phosphate as substrates, the corresponding dehydrogen-
ases cause a direct reduction of ubiquinone, by-passing complex
I. The respiration observed with these substrates is dependent
only on complexes III and IV. (The reduction of ubiquinone by
succinate dehydrogenase and glycerol-3-P dehydrogenase in
combination is not rate-limiting because the addition of either
succinate or glycerol-3-P alone to a suspension of permeabilized
143B cells allows at least 80% of the respiration rate that is
supported by both substrates in combination.2) The reagents
N,N,N9,N9-tetramethyl-p-phenylenediamine (TMPD) and ascor-
bate reduce intracellular cytochrome c, thereby allowing respi-
ration due to complex IV activity alone to be measured. The
substrate-dependent respiration rates reflect the activities of
the individual complexes of the respiratory chain, because com-
plex IV activity is usually higher than complex III activity,
which in turn is usually higher than complex I activity.
Fig. 3a shows that the malate/glutamate-driven respiration
rates in the 11778 mutation-carrying cell lines are clearly lower
than those of the control cell lines, whereas the succinate/
glycerol-3-P- and the TMPD/ascorbate-driven respiration rates
are comparable to those of the controls. This observation is
consistent with the occurrence of a specific defect in the respi-
ratory chain at the level of complex I. Control transformants
C2.C1 and C2.H1, which exhibit an unusually low oxygen con-
sumption rate (Fig. 2), also show a low malate/glutamate-
driven respiration. However, the succinate/glycerol-3-P- and
TMPD/ascorbate-driven respiration rates in these cell lines are
also reduced, a result which points to an overall reduction in
mitochondrial respiratory enzyme activity. Fig. 3b shows the
glutamate/malate-driven respiration rates of the various cell
lines, which reflect their complex I activity, normalized to their
succinate/glycerol-3-P-driven respiration rates, which reflect
their complex III activity. It is clear that the complex I-depend-
ent respiration rate in the cell lines carrying the 11778 muta-
tion is specifically decreased when compared to the control cell
lines, the difference being statistically very significant.
Enzyme Activities—The NADH dehydrogenase activity was
measured in the isolated mitochondrial fraction from two con-
trol and two LHON transformants, using as electron acceptor
DB, which is a soluble analogue of the endogenous acceptor,
ubiquinone. Cytochrome c oxidase activity was also measured
in the same preparations in order to correct the NADH:DB
oxidoreductase activities for differences in mitochondrial mem-
brane content among the crude mitochondrial preparations
isolated from different clones. As shown in Table I, the values
for NADH:DB oxidoreductase activity varied somewhat, but
when the activities were normalized to cytochrome c oxidase
activity, there was no consistent difference between mutant
and wild type transformants (p 5 0.60).
Growth Properties of ND4 11778 Mutation-carrying r0 Cell
Transformants and Control Cells—Table II shows that the
growth rate in glucose-containing medium (DMEM) of the
11778 mutation-carrying cell lines is not significantly different2 G. Hofhaus, unpublished data.
TABLE I
Measurement of NADH:DB oxidoreductase activity in the sonicated mitochondrial fraction from 11778 mutation carrying and control cells
Enzyme activities are expressed in nmol z min21 z (mg protein)21. The NADH:DB oxidoreductase activity was measured in triplicate, and the
cytochrome c oxidase activity, in triplicate or quadruplicate. Numbers in parentheses represent two standard errors of the mean. The values for
NADH:DB activity represent the total activity; however, more than 95% of this activity was rotenone-sensitive.
Controls LHON
C1.C11 C2.A8 Le1.4.2 Le2.F10
NADH:DB 60.5 (0.92) 23.7 (0.81) 26.6 (1.10) 26.0 (0.40)
Cytochrome c oxidase 230 (13.9) 126 (0.65) 81 (2.0) 126 (2.2)
NADH:DB
Cytochrome c oxidase
0.26 (0.016) 0.19 (0.007) 0.33 (0.016) 0.21 (0.005)
TABLE II
Comparison of growth and respiration properties of 11778 mutation carrying and control cells
The doubling time of different cell lines in DMEM was determined from growth curves. The extent of growth of the different cell lines in medium
containing galactose as the only sugar, and in medium containing glucose at 100 h after seeding was determined from growth curves.
Malate/glutamate-driven respiration and succinate/glycerol 3-phosphate-driven respiration rates were measured in triplicate (Fig. 3a) and are
expressed as fmol z min21 z cell21.
Cell line Doubling timein DMEM
No. of cells in galactose at 100 h Malate/glutamate
respiration
Succinate/glycerol-3-P
respirationNo. of cells in glucose at 100 h
Controls
143B 16.8 0.20 2.5 3.4
pT3 18.3 0.36 3.3 4.4
C1.C11 21.6 0.33 3.2 4.9
C2.A8 30.9 0.25 3.1 4.4
C2.C1 19.3 0.15 1.1 1.4
Mean 21.4 0.26 2.6 3.7
LHON
Le1.4.2 28.2 0.12 1.4 2.9
Le2.F10 22.6a 0.14a 1.8 4.4
Le2.H4 20.5 0.14 1.6 3.5
Mean 23.8 0.13 1.6 3.6
pb 0.42 0.014 0.004 0.89
Correlation analysis r
Galactose/glucose cell number ratio versus malate/glutamate respiration 0.92
Galactose/glucose cell number ratio versus succinate/glycerol-3-P respiration 0.62
a Average of two values.
b Probability that the control data set and the LHON data set derive from two populations having the same mean (Student’s t test).
MtDNA-linked Dysfunction in Leber’s Hereditary Optic Neuropathy 13159
from that measured in the control cell lines. In order to inves-
tigate whether the complex I defect detected in the r0 cell
transformants carrying the 11778 mutation affected their
growth capacity in a selective medium, these transformants
were tested for growth in a medium in which galactose replaced
glucose. In this type of medium, cells deficient in respiratory
function (20, 40–42) are greatly curtailed in their growth rate.
Fig. 4 compares the growth curves in galactose medium and
glucose medium of the transformant Le1.4.2, carrying the
11778 mutation, with those of control cells, 143B and C1.C11.
Clearly the cells carrying the mutation grew only at a minimal
rate in the galactose medium, whereas control cells showed a
substantial growth rate in this medium, although reduced as
compared to their growth in glucose-containing medium.
The growth curves in the two media were determined for
several mutant and control cell lines. Table II shows the ratios
of the number of cells in the galactose medium to the number of
cells in the glucose medium after a 100-h incubation, as deter-
mined from the growth curves. It is clear that the extent of
growth allowed by the galactose medium relative to that in
glucose medium was reduced from an average of 26% in the
control cell lines to an average of 13% in the mutant cell lines,
the difference being statistically significant at the 99% confi-
dence level. Table II shows also that the ratio of growth in
galactose to growth in glucose of the various cell lines corre-
lates, with a high level of significance (r 5 0.92), with the
malate/glutamate-dependent respiration rate, but not with the
succinate/glycerol-3-P-driven respiration rate (r 5 0.62). The
correlation holds also for the transformant C2.C1 that grows
relatively poorly in galactose medium and has a very low
malate/glutamate-dependent respiration rate.
DISCUSSION
The central result reported here is the demonstration that
specific biochemical defects associated with the 11778 LHON
mutation could be transferred with mitochondria into r0206
mtDNA-less cells, thereby establishing a cellular model for this
disease in a foreign nuclear background. This result is partic-
ularly significant, because the tissue specificity, low pen-
etrance, and gender bias of LHON have strongly suggested that
a nuclear factor(s) plays a role in the manifestation of the
disease. It is not known whether the r0206 nuclear background
carries the putative change in gene content or activity that
contributes to the phenotype in affected individuals. The fre-
quency of the X-linked allele that has been suggested to be
essential for the manifestation of the pathogenetic effects of the
11778 ND4 mutation (16) has been estimated to be ;0.08 (11,
15). Further investigations using the r0206 cellular model de-
scribed here and similar models constructed with genetically
different r0 cell recipients, as well as extending the analysis to
asymptomatic individuals carrying the 11778 ND4 mutation in
homoplasmic form, should be able to distinguish the effects of
the mtDNA mutation from those of the putative nuclear fac-
tor(s), and may lead to the identification of this factor.
In the present work, all the r0 transformants carrying the
11778 mutation exhibited a clearly defective phenotype, which
could unambiguously be associated with the mutation. In par-
ticular, they showed a very significant decrease in NADH
dehydrogenase-dependent respiration after digitonin perme-
abilization. However, we were not able to detect a reduction in
NADH dehydrogenase activity in sonicated mitochondria from
the transformants using NADH and a water-soluble ubiqui-
none analogue in a photometric assay. These results are in
agreement with those obtained by Majander and colleagues
(13) and Larsson et al. (12) who used similar assays to ours on
intact and disrupted mitochondria from individuals with the
11778 mutation. Vergani et al. (43), who have recently reported
the transfer into r0206 cells of mitochondria from patients’ cells
carrying the 11778 ND4 mutation, also failed to observe a
decrease in NADH:Q oxidoreductase activity, as measured in
total cell sonicates of the transformants. However, these au-
thors did not carry out any polarographic measurements on
permeabilized transformant cells.
As to the basis for the apparent discrepancy between the
data from the direct and those from the indirect assays in our
experiments and in those by Larsson et al. (12) and Majander
et al. (13), it should be noted that, in the assays on digitonin-
permeabilized cells or on isolated intact mitochondria, the
NADH is possibly delivered directly to the binding site by
substrate dehydrogenases, which have been suggested to be
closely associated with complex I (44). The 11778 ND4 muta-
tion could conceivably interfere with the interaction of complex
I with NAD-linked dehydrogenases, and, therefore, with the
channeling of NADH to complex I in the putative multienzyme
complex (13), and thereby cause a decrease in enzymatic activ-
ity. This effect would not be observed in enzymatic assays in
FIG. 4. Growth curves of 143B, C1.C11, and Le1.4.2. Glucose,
growth curve for cells grown in DMEM containing 4.5 mg of glucose/ml
and 0.11 mg of pyruvate/ml; galactose, growth curve for cells grown in
DMEM lacking glucose and containing instead 0.9 mg of galactose/ml
and 0.5 mg of pyruvate/ml.
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which an excess of NADH, rather than an oxidizable substrate,
is added to the mitochondrial fraction.
Another factor to take into consideration is the use of hydro-
philic analogues of ubiquinone in the enzyme assays. If the
diffusion of these substrates into the membrane is the rate-
limiting step (45), these assays would not measure the full
activity of the wild-type enzyme. As a consequence, decreases
in the activity of the enzyme may not be easily detectable.
Degli Esposti et al. (14) have reported that, in mitochondria
from individuals carrying the 11778 mutation, the NADH:Q
reductase has a decreased sensitivity to the specific inhibitor
rotenone, as tested in an assay with the ubiquinone analogue
UBQ, as well as altered Km values for this analogue and an-
other analogue, ubiquinone-2. On the basis of these findings,
they have proposed that the binding site for ubisemiquinone is
altered, and, as a consequence, the destabilized ubisemiqui-
none has an increased tendency to dismutate, with a resulting
loss in the energy conserving function of complex I. More in-
formation on the topology of complex I and the position and role
of ND4 in it may be required for a full understanding of the
basis of the discrepancy between the results of the direct spec-
trophotometric assays and those of the indirect assays of com-
plex I activity.
In addition to detecting a decrease in NADH dehydrogenase-
dependent respiration, we have been able to demonstrate for
the first time a specific growth impairment in cells carrying a
LHON mutation in a medium containing galactose in place of
glucose. In glucose-containing medium, cultured wild-type
mammalian cells are known to derive 45–60% of their ATP
from glycolysis (46, 47); therefore, in this medium, even respi-
ration-deficient cells can grow, although possibly at a reduced
rate, relying predominantly or exclusively on glycolysis for the
production of ATP. On the other hand, galactose is metabolized
through the glycolytic pathway only very slowly (47); therefore,
in galactose-containing medium, respiration-deficient cells
would be expected to be affected in their growth rate. According
to this interpretation, the decrease in respiratory efficiency of
the LHON transformants reduces their rate of ATP production
by oxidative phosphorylation to an extent sufficient to affect
their growth capacity in galactose-containing medium. It
should be mentioned that Vergani et al. (43) reported a de-
crease in growth rate of cells carrying the 11778 mutation in
standard glucose-containing medium, that was not observed in
our transformants.
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